# US 2018/0021456 A1 · Self-assembled targeted inclusion complexes for drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021456 A1
- Document ID: US20180021456A1
- Status: Published application
- Kind: A1
- Application number: 15/547,815
- Filed: 2016-02-04
- Published: 2018-01-25
- Earliest claimed: 2015-02-04
- Assignees: University of South Florida
- Applicants: University of South Florida
- Inventors: SHU-FENG ZHOU; JUN TAN; JUAN-JUAN YIN
- Web page: https://patentgrep.com/patent/US20180021456A1

## CPC

- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- C08B 37/0012: {Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof}
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

Inclusion complexes are provided containing a targeted carrier non-covalently associated with an active agent. The targeted carrier includes an inclusion host that binds the active agent or a binding partner attached to the active agent. The targeted carrier includes a targeting moiety attached to the inclusion host or to a polymer or linker attached thereto. Pharmaceutical formulations of the inclusion complexes are provided. Methods of making the inclusion complexes and formulations thereof are provided. Methods of using the inclusion complexes and formulations are provided. In some embodiments the inclusion complex includes a progesterone or estrogen targeting moiety that targets the inclusion complex to cancer cells. The targeting can cause internalization of the active agent in the target cells. In some embodiments the active agent is an anthracycline such as doxorubicin and the target cells are cancer cells.

## Claims

### Claim 1

An inclusion complex comprising:
a targeted carrier comprising an inclusion host and having a targeting moiety attached thereto, and
an active agent or precursor thereof non-covalently associated with the inclusion host.

### Claim 2 (depends on 1)

The inclusion complex of claim 1, wherein the inclusion host is selected from the group consisting of crown ethers, cyclodextrins, calixarenes, and cucurbituril.

### Claim 3 (depends on 2)

The inclusion complex of claim 2, wherein the cyclodextrin is selected from the group consisting of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and combinations thereof.

### Claim 4 (depends on 1)

The inclusion complex of claim 1, wherein the precursor comprises a conjugate of the active agent and a binding partner that non-covalently binds to the inclusion host.

### Claim 5 (depends on 4)

The inclusion complex of claim 4, wherein the binding partner non-covalently binds to the inclusion host via an interaction selected from the group consisting of π-bonding, cation-π, Van der Walls, and hydrogen-bonding interactions.

### Claim 6 (depends on 4)

The inclusion complex of claim 4, wherein the binding partner is selected from the group consisting of phenyl groups, lipids such as cholesterol, naphthol derivatives, and cage-like cycloalkanes such as adamantane, diamantine, and iceane.

### Claim 7 (depends on 1)

The inclusion complex of claim 1, wherein the targeting moiety is selected from the group consisting of a protein, a peptide, a nucleic acid, and a small molecule.

### Claim 8 (depends on 1)

The inclusion complex of claim 1, wherein the targeting moiety targets a cell surface receptor that results in internalization of the active agent.

### Claim 9 (depends on 1)

The inclusion complex of claim 1, wherein the targeting moiety is estrogen or progesterone.

### Claim 10 (depends on 1)

The inclusion complex of claim 1, wherein the targeted carrier comprises a polymer covalently associated with the inclusion host, optionally wherein the targeting moiety is covalently associated with the polymer.

### Claim 11 (depends on 10)

The inclusion complex of claim 10, wherein the polymer comprises a biodegradable polymer such as a poly(alkynoic acid) or a copolymer or derivative thereof.

### Claim 12 (depends on 10)

The inclusion complex of claim 10, wherein the polymer comprises a poly(alkylene oxide) such as poly(ethylene oxide), poly(propylene oxide), or a copolymer or derivative thereof.

### Claim 13 (depends on 1)

The inclusion complex of claim 1, wherein the inclusion host is a cyclodextrin;
wherein the targeting moiety is estrogen or progesterone;
wherein the active agent is doxorubicin; and
wherein the precursor comprises adamantane covalently attached to the doxorubicin;
optionally wherein the targeted carrier comprises a polymer covalently associated with the cyclodextrin.

### Claim 14 (depends on 1)

A pharmaceutical formulation for treating or preventing a disease or disorder in a subject in need thereof comprising an effective amount of an inclusion complex according to claim 1 and a pharmaceutically acceptable solvent.

### Claim 15 (depends on 14)

The pharmaceutical formulation of claim 14, wherein the disease or disorder is cancer.

### Claim 16 (depends on 1)

A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering an effective amount of an inclusion complex according to claim 1 to the subject.

### Claim 17 (depends on 1)

A method of making an inclusion complex according to claim 1, comprising providing a targeted carrier comprising an inclusion host and having a targeting moiety attached thereto, and
providing an active agent or a precursor thereof, wherein the active agent or precursor non-covalently associates with the inclusion host to form the inclusion complex.

### Claim 18 (depends on 17)

The method of claim 17, further comprising providing the inclusion host having a reactive coupling group attached thereto; and
reacting the targeting moiety to form a covalent bond with the reactive coupling group to form the targeted carrier.

### Claim 19 (depends on 18)

The method of claim 18, wherein the reactive coupling group is an amine and the targeting moiety comprises an amine-reactive group.

### Claim 20 (depends on 17)

The method of claim 17, further comprising conjugating a binding partner to the active agent to form the precursor, wherein the binding partner non-covalently binds to the inclusion host via an interaction selected from the group consisting of π-bonding, cation-π, Van der Walls, and hydrogen-bonding interactions.
